%0 Journal Article
%T Evaluation of the therapeutic efficacy of lamivudine combined with plasma exchange for treating acute-on-chronic hepatitis B liver failure
%A HU Qijiang
%J Journal of Clinical Hepatology
%D 2013
%I Journal of Clinical Hepatology
%X ObjectiveTo observe the clinical effects of lamivudine antiviral therapy combined with plasma exchange in patients with acute-on-chronic hepatitis B liver failure. MethodsForty-seven patients (treatment group) were administered lamivudine and underwent plasma exchange. An additional forty-five patients (control group) were administered lamivudine but no plasma exchange. Otherwise, all patients received the same basic medical treatment. The two groups were further divided into three sub-groups according to the model for end-stage liver disease (MELD) score: £¼30, 30-39, and ¡Ý40. The significance of differences in survival rates between the groups and sub-groups was determined by the ¦Ö2 test. ResultsThe overall survival rate was significantly better in the treatment group (63.82% vs. control group: 44.44%; ¦Ö2=4.31, P£¼0.05). Within the treatment group, the survival rates were highest in the 30-39 MELD score sub-group (71.42%), which was significantly different from survival rate in the same sub-group of the controls (vs. 38.10%; ¦Ö2=4.71, P£¼0ª±05). The other two MELD score sub-groups showed no significant differences between the treatment and control groups (all P£¾0.05). ConclusionCombined therapy consisting of lamivudine treatment and plasma exchange can improve the survival rate of patients with acute-on-chronic hepatitis B liver failure who have MELD scores between 30 and 39.
%K liver failure
%K plasma exchange
%K lamivudine
%K hepatitis B
%U http://www.lcgdbzz.org/qk_content.asp?id=5281&ClassID=115155845